Floatz logo

Brimonidine

Relapsing-Remitting Multiple Sclerosis (RRMS)

BiogenSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

80 Active assets in the Relapsing-Remitting Multiple Sclerosis (RRMS) cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB

View all 50 →

Same molecule, other indications

Brimonidine is also rated in:

prostate cancerDormant
B
Indicative ·
56 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Folate Receptor-Alpha PositiveDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →